


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:47:24Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405528" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405528</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>scirep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405528</article-id><article-id pub-id-type="pmcid-ver">PMC12405528.1</article-id><article-id pub-id-type="pmcaid">12405528</article-id><article-id pub-id-type="pmcaiid">12405528</article-id><article-id pub-id-type="pmid">40897777</article-id><article-id pub-id-type="doi">10.1038/s41598-025-17505-0</article-id><article-id pub-id-type="publisher-id">17505</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of combined undenatured type II collagen and hydrolysed collagen supplementation in knee osteoarthritis: a randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yuenyongviwat</surname><given-names initials="V">Varah</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anusitviwat</surname><given-names initials="C">Chirathit</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tuntarattanapong</surname><given-names initials="P">Pakjai</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hongnaparak</surname><given-names initials="T">Theerawit</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Iamthanaporn</surname><given-names initials="K">Khanin</given-names></name><address><email>khanin.i@psu.ac.th</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0575ycz84</institution-id><institution-id institution-id-type="GRID">grid.7130.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 1162</institution-id><institution>Department of Orthopedics, Faculty of Medicine, </institution><institution>Prince of Songkla University, </institution></institution-wrap>Hat Yai, 90110 Songkhla Thailand </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>32313</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41598_2025_Article_17505.pdf"/><abstract id="Abs1"><p id="Par1">Collagen supplements have gained significant market popularity, with numerous products claiming to improve knee osteoarthritis symptoms. Previous clinical studies have primarily evaluated individual collagen formulations, with most being industry-sponsored, which raises potential bias concerns. This study aimed to evaluate the efficacy of combined undenatured type II collagen (UC-II) and hydrolysed collagen supplementation in patients with knee osteoarthritis. In this randomised, double-blind, placebo-controlled trial, 68 patients with knee osteoarthritis were divided into two groups: one receiving collagen supplements (tablets containing hydrolysed collagen and UC-II) and the other receiving a placebo. Clinical outcomes, including pain intensity (Verbal Numerical Rating Scale), functional outcomes (Knee Injury and Osteoarthritis Outcome Score [KOOS]), rescue medication consumption, and patient satisfaction, were assessed at baseline, 2, 6, and 12 weeks. Baseline demographic characteristics were comparable between the collagen and placebo groups. Both groups showed significant improvements in pain intensity (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and KOOS scores over time. However, no significant differences were observed between the groups in terms of pain intensity, functional outcomes, rescue medication consumption, or patient satisfaction (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). No adverse effects were reported in either group. Combined UC-II and hydrolysed collagen supplementation over 12 weeks did not demonstrate superior efficacy compared with that of the placebo in managing knee osteoarthritis symptoms. Further research is required to explore the potential long-term benefits of combined collagen supplementation.</p><p id="Par2"><bold>Clinical Trial Registration</bold>: ClinicalTrials.gov (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06229951">NCT06229951</ext-link>): registered on January 16, 2024.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Undenatured type II collagen</kwd><kwd>Hydrolysed collagen</kwd><kwd>Knee osteoarthritis</kwd><kwd>Randomised trial</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Medical research</kwd><kwd>Rheumatology</kwd></kwd-group><funding-group><award-group><funding-source><institution>Medical Council of Thailand (Police General Dr. Jongjate Aojanepong Foundation)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par3">Knee osteoarthritis (OA), which is characterised by the progressive degradation of articular cartilage, exhibits a significantly increasing prevalence owing to population aging and rising obesity rates<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. This condition substantially affects the quality of life of patients and poses significant socioeconomic implications<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. Current treatment modalities encompass a spectrum of interventions, ranging from behavioural modifications and pharmacological interventions to intra-articular injections and surgical procedures<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">Collagen supplements have become increasingly popular in recent years, with a wide range of products claiming to improve the symptoms of knee OA. Collagen, the primary structural protein in articular cartilage, provides joint structure and elasticity<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Various forms of collagen supplements have emerged in clinical practice, including porcine collagen peptides, bovine collagen peptides, undenatured type II collagen (UC-II), and hydrolysed collagen from chicken cartilage<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Mechanistic studies have demonstrated that collagen may stimulate cartilage regeneration by enhancing the synthesis of extracellular matrix macromolecules<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In addition, research has revealed its immunomodulatory effects, preventing joint damage through the induction and migration of regulatory T cells and production of anti-inflammatory cytokines<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par5">Clinical investigations of collagen supplementation in patients with OA have shown promising results, with several studies demonstrating improvements in pain reduction and knee function when using hydrolysed collagen or UC-II<sup><xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref></sup>. These findings suggested the potential therapeutic benefits of collagen supplementation in managing knee OA symptoms.</p><p id="Par6">However, previous clinical studies have evaluated individual collagen formulations, with distinct trials investigating either hydrolysed collagen or UC-II in patients with OA. Although these single-formulation studies reported improvements in pain and knee function, most were industry-sponsored, raising potential bias concerns. Furthermore, the heterogeneity in collagen types and dosages across studies complicates the interpretation of optimal supplementation protocols. To date, no study has investigated the potential synergistic effects of different collagen formulations. Given these limitations, we conducted this manufacturer-independent trial to evaluate the efficacy of combined hydrolysed collagen and UC-II compared with that of placebo in knee OA management.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par7">This randomised, double-blind, placebo-controlled trial was conducted at the university hospital between November 2023 and August 2024. The study protocol was approved by the institutional review board on September 29, 2023. The trial is registered with ClinicalTrials.gov (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT06229951">NCT06229951</ext-link>) and was registered on January 16, 2024. Written informed consent was obtained from all participants before enrolment. All methods were performed in accordance with the relevant ethical guidelines and regulations, including the Declaration of Helsinki and applicable local regulations.</p><p id="Par8">Patients diagnosed with knee OA seeking treatment at the outpatient orthopaedic clinic were recruited. The diagnosis was confirmed via clinical examination and radiographic findings. Patients were eligible if they were aged 50&#8211;80 years, had predominant symptoms in the medial knee compartment, demonstrated Kellgren&#8211;Lawrence radiographic classification grades of 2 or 3, had knee varus angulation&#8201;&lt;&#8201;10&#176;, and were able to walk without assistive devices. Patients were excluded if they had a history of knee surgery; received intra-articular steroid injection within the past 6 months; had systemic arthritis, neurological or muscular impairment of the lower extremities, or kidney disease with glomerular filtration rate&#8201;&lt;&#8201;60 mL/min/1.73 m<sup>2</sup>; or had a history of allergy to meloxicam, celecoxib, or collagen.</p><p id="Par9">After screening 87 patients, 68 eligible participants were enrolled and randomly allocated to either the collagen (<italic toggle="yes">n</italic>&#8201;=&#8201;34) or placebo (<italic toggle="yes">n</italic>&#8201;=&#8201;34) group (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Randomisation was performed using a computer-generated sequence with a block size of four. The allocation sequence was concealed using opaque, sealed, and numbered envelopes that were opened sequentially by an independent research assistant who was not involved in clinical care or outcome assessment after confirming participant eligibility. The participants, treating physicians, and outcome assessors were blinded to the group allocation throughout the study period.</p><p id="Par10">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flow diagram of participant selection.</p></caption><graphic id="d33e260" position="float" orientation="portrait" xlink:href="41598_2025_17505_Fig1_HTML.jpg"/></fig>
</p><p id="Par11">Participants in the collagen group received daily supplement tablets containing 480&#160;mg hydrolysed collagen and 20&#160;mg UC-II (Bangkok Drug Co., Ltd., Bangkok, Thailand), whereas those in the placebo group received tablets containing maltodextrin. The dosing schedule for both consisted of two tablets administered before bedtime. All participants received standardised care, including patient education, muscle-strengthening exercises, and rescue medication (meloxicam [7.5&#160;mg] or celecoxib [200&#160;mg] for those allergic to meloxicam) as needed for pain management.</p><p id="Par12">Follow-up visits were scheduled at baseline and at weeks 2, 6, and 12. A blinded independent research assistant performed all the assessments. The primary outcome measure was pain level, measured using the Verbal Numerical Rating Scale (VNRS). Secondary outcomes included knee function and quality of life assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS), rescue medication consumption, patient satisfaction measured using the VNRS, and monitoring of adverse effects.</p><p id="Par13">All statistical analyses were performed using R software (version 4.4.1; R Foundation for Statistical Computing, Vienna, Austria). The Kolmogorov&#8211;Smirnov test was used to assess the normality of data distribution. Independent <italic toggle="yes">t-</italic>tests were used to compare normally distributed continuous variables (age, weight, height, and body mass index [BMI]) between groups. Categorical variables (sex, Kellgren&#8211;Lawrence classification, and history of diabetes) were analysed using the chi-square test. Non-parametric data, including pain scores (VNRS), KOOS subscales, rescue medication consumption, and patient satisfaction scores, were compared between groups using the Mann&#8211;Whitney U test. Statistical uncertainty was assessed using 95% confidence intervals for the differences between the two groups. A Generalized Estimating Equations (GEE) analysis was performed to examine the effect of time and group on pain scores (VNRS) over a 12-week period. An intention-to-treat analysis was performed, including all randomised participants regardless of protocol adherence or study completion. Statistical significance was set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p><p id="Par14">Sample size calculation was performed based on previous data from Kumar et al.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> To detect a clinically meaningful difference in pain scores between groups, assuming a two-tailed &#945; of 0.05 and &#946; of 0.10 (power&#8201;=&#8201;0.90), 28 participants were required per group. The final sample size was increased to 34 participants per group (<italic toggle="yes">n</italic>&#8201;=&#8201;68) to account for an anticipated dropout rate of 20%.</p></sec><sec id="Sec3"><title>Results</title><p id="Par15">The baseline demographic characteristics, including sex, age, weight, height, BMI, Kellgren&#8211;Lawrence classification, and history of diabetes, were comparable between the collagen and control groups (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par16">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">Collagen group<break/><italic toggle="yes">n</italic>&#8201;=&#8201;34</th><th align="left" colspan="1" rowspan="1">Control group<break/><italic toggle="yes">n</italic>&#8201;=&#8201;34</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex (male: female)</td><td align="left" colspan="1" rowspan="1">5:29</td><td align="left" colspan="1" rowspan="1">4:30</td><td align="left" colspan="1" rowspan="1">0.720</td></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">63.59&#8201;&#177;&#8201;7.11*</td><td align="left" colspan="1" rowspan="1">65.15&#8201;&#177;&#8201;6.61*</td><td align="left" colspan="1" rowspan="1">0.352</td></tr><tr><td align="left" colspan="1" rowspan="1">Weight (kg)</td><td align="left" colspan="1" rowspan="1">63.75&#8201;&#177;&#8201;11.04*</td><td align="left" colspan="1" rowspan="1">63.53&#8201;&#177;&#8201;9.04*</td><td align="left" colspan="1" rowspan="1">0.930</td></tr><tr><td align="left" colspan="1" rowspan="1">Height (cm)</td><td align="left" colspan="1" rowspan="1">156.69&#8201;&#177;&#8201;5.72*</td><td align="left" colspan="1" rowspan="1">154.74&#8201;&#177;&#8201;6.73*</td><td align="left" colspan="1" rowspan="1">0.201</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">26.01&#8201;&#177;&#8201;4.59*</td><td align="left" colspan="1" rowspan="1">26.51&#8201;&#177;&#8201;3.31*</td><td align="left" colspan="1" rowspan="1">0.602</td></tr><tr><td align="left" colspan="1" rowspan="1">KL classification (II: III)</td><td align="left" colspan="1" rowspan="1">23/11</td><td align="left" colspan="1" rowspan="1">23/11</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes (%)</td><td align="left" colspan="1" rowspan="1">23.5%</td><td align="left" colspan="1" rowspan="1">23.5%</td><td align="left" colspan="1" rowspan="1">1</td></tr></tbody></table><table-wrap-foot><p>*Values are expressed as the mean&#8201;&#177;&#8201;SD.</p><p><italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">KL</italic> Kellgren&#8211;Lawrence, <italic toggle="yes">SD</italic> standard deviation.</p></table-wrap-foot></table-wrap>
</p><p id="Par17">Pain intensity measured using the VNRS demonstrated significant improvement from baseline in both groups at all follow-up time points (2, 6, and 12 weeks; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). However, between-group comparisons revealed no significant differences at any time point. (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) A Generalized Estimating Equations analysis revealed significant reductions in VNRS pain scores over time in both groups. At the 12-week follow-up, the collagen group showed a mean pain reduction of 2.21 points (B = -2.21, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, 95%CI [-3.11, -1.30]), while the control group showed a reduction of 2.29 points (B = -2.29, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, 95%CI [-3.33, -1.26]) compared to baseline. The difference in pain score reduction between the groups was minimal (0.08 points) and not statistically significant. (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>)</p><p id="Par18">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Verbal numerical rating scale (VNRS) for pain level.</p></caption><graphic id="d33e428" position="float" orientation="portrait" xlink:href="41598_2025_17505_Fig2_HTML.jpg"/></fig>
</p><p id="Par19">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Comparison of verbal numerical rating scale (VNRS) for pain and satisfaction scores between collagen and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1"/><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">2 weeks</th><th align="left" colspan="1" rowspan="1">6 weeks</th><th align="left" colspan="1" rowspan="1">12 weeks</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">VNRS for pain</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">5.5 (2)</td><td align="left" colspan="1" rowspan="1">4 (2.5)</td><td align="left" colspan="1" rowspan="1">3 (3)</td><td align="left" colspan="1" rowspan="1">3(3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">6 (2)</td><td align="left" colspan="1" rowspan="1">4 (2.3)</td><td align="left" colspan="1" rowspan="1">3 (3)</td><td align="left" colspan="1" rowspan="1">3 (3)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">0.358</td><td align="left" colspan="1" rowspan="1">0.980</td><td align="left" colspan="1" rowspan="1">0.861</td><td align="left" colspan="1" rowspan="1">0.789</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1, 0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1, 1</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1, 1</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1, 1</td></tr><tr><td align="left" rowspan="4" colspan="1">VNRS for satisfaction</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">8 (3)</td><td align="left" colspan="1" rowspan="1">9 (2)</td><td align="left" colspan="1" rowspan="1">8.5 (1.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">7 (3)</td><td align="left" colspan="1" rowspan="1">8 (3)</td><td align="left" colspan="1" rowspan="1">9 (2)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.227</td><td align="left" colspan="1" rowspan="1">0.355</td><td align="left" colspan="1" rowspan="1">0.126</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0, 2</td><td align="left" colspan="1" rowspan="1">0, 1</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1, 0</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">CI</italic> confidence interval.</p></table-wrap-foot></table-wrap>
</p><p id="Par20">The KOOS assessment showed similar baseline scores between groups across all subscales (Pain, Symptoms, Activities of Daily Living, Sports/Recreation, and Quality of Life; <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). Both groups demonstrated improvements in KOOS scores over time; however, no significant between-group differences were observed throughout the study period. (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>)</p><p id="Par21">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Comparison of Knee injury and Osteoarthritis Outcome Score&#160;(KOOS) between collagen and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1"/><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">2 weeks</th><th align="left" colspan="1" rowspan="1">6 weeks</th><th align="left" colspan="1" rowspan="1">12 weeks</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Pain</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">69 (20)</td><td align="left" colspan="1" rowspan="1">77 (17)</td><td align="left" colspan="1" rowspan="1">80 (26)</td><td align="left" colspan="1" rowspan="1">83 (15)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">63 (23)</td><td align="left" colspan="1" rowspan="1">75 (13)</td><td align="left" colspan="1" rowspan="1">78 (9)</td><td align="left" colspan="1" rowspan="1">83 (18)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">0.325</td><td align="left" colspan="1" rowspan="1">0.887</td><td align="left" colspan="1" rowspan="1">0.912</td><td align="left" colspan="1" rowspan="1">0.863</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;3, 11</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;6, 6</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;8, 6</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;5, 6</td></tr><tr><td align="left" rowspan="4" colspan="1">Symptoms</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">71 (23)</td><td align="left" colspan="1" rowspan="1">82 (15)</td><td align="left" colspan="1" rowspan="1">82 (25)</td><td align="left" colspan="1" rowspan="1">86 (19)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">75 (13)</td><td align="left" colspan="1" rowspan="1">81 (18)</td><td align="left" colspan="1" rowspan="1">82 (16)</td><td align="left" colspan="1" rowspan="1">84 (15)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">0.887</td><td align="left" colspan="1" rowspan="1">0.820</td><td align="left" colspan="1" rowspan="1">0.725</td><td align="left" colspan="1" rowspan="1">0.839</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;7, 7</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;4, 7</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;7, 4</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;4, 7</td></tr><tr><td align="left" rowspan="4" colspan="1">Activities of daily living</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">65 (30)</td><td align="left" colspan="1" rowspan="1">67 (24)</td><td align="left" colspan="1" rowspan="1">69 (23)</td><td align="left" colspan="1" rowspan="1">72 (18)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">60 (18)</td><td align="left" colspan="1" rowspan="1">65 (16)</td><td align="left" colspan="1" rowspan="1">69 (17)</td><td align="left" colspan="1" rowspan="1">75 (21)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">0.102</td><td align="left" colspan="1" rowspan="1">0.443</td><td align="left" colspan="1" rowspan="1">0.768</td><td align="left" colspan="1" rowspan="1">0.610</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1, 16</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;4, 9</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;8, 6</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;9, 6</td></tr><tr><td align="left" rowspan="4" colspan="1">Sports and recreation</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">15 (25)</td><td align="left" colspan="1" rowspan="1">20 (26)</td><td align="left" colspan="1" rowspan="1">23 (26)</td><td align="left" colspan="1" rowspan="1">23 (28)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">15 (20)</td><td align="left" colspan="1" rowspan="1">15 (16)</td><td align="left" colspan="1" rowspan="1">18 (15)</td><td align="left" colspan="1" rowspan="1">25 (21)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">0.216</td><td align="left" colspan="1" rowspan="1">0.446</td><td align="left" colspan="1" rowspan="1">0.354</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">0, 10</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;5, 10</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;5, 10</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;10, 10</td></tr><tr><td align="left" rowspan="4" colspan="1">Quality of life</td><td align="left" colspan="1" rowspan="1">Collagen</td><td align="left" colspan="1" rowspan="1">35 (25)</td><td align="left" colspan="1" rowspan="1">50 (12)</td><td align="left" colspan="1" rowspan="1">50 (15)</td><td align="left" colspan="1" rowspan="1">69 (25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Control</td><td align="left" colspan="1" rowspan="1">38 (25)</td><td align="left" colspan="1" rowspan="1">50 (14)</td><td align="left" colspan="1" rowspan="1">50 (25)</td><td align="left" colspan="1" rowspan="1">69 (25)</td></tr><tr><td align="left" colspan="1" rowspan="1">p value</td><td align="left" colspan="1" rowspan="1">0.841</td><td align="left" colspan="1" rowspan="1">0.923</td><td align="left" colspan="1" rowspan="1">0.421</td><td align="left" colspan="1" rowspan="1">0.804</td></tr><tr><td align="left" colspan="1" rowspan="1">95% CI</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;6, 6</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;6, 6</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;12, 0</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;6, 0</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IQR</italic> interquartile range, <italic toggle="yes">CI</italic> confidence interval.</p></table-wrap-foot></table-wrap>
</p><p id="Par22">Both groups showed a decreasing trend in rescue medication consumption over time. At 2 weeks, the collagen group had a lower median consumption compared with that in the control group (1 [IQR, 6] vs. 4 [IQR, 10] tablets), although this difference was not significant (<italic toggle="yes">p</italic>&#8201;=&#8201;0.135). The median consumption continued to decrease at 6 weeks (collagen: 0 [IQR, 5]; control: 0.5 [IQR, 10]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.48) and reached similar levels at 12 weeks (collagen: 0 [IQR, 4]; control: 0 [IQR, 5]; <italic toggle="yes">p</italic>&#8201;=&#8201;0.518). (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>)</p><p id="Par23">The patient satisfaction scores were consistently high in both groups throughout the study period. The collagen group reported median satisfaction scores of 8 (IQR, 3), 9 (IQR, 2), and 8.5 (IQR, 1.3) at 2, 6, and 12 weeks, respectively. Similarly, the control group reported median scores of 7 (IQR, 3), 8 (IQR, 3), and 9 (IQR, 2), respectively. No significant differences were observed between the groups at any time point (<italic toggle="yes">p</italic>&#8201;=&#8201;0.227, 0.355, and 0.126 at 2, 6, and 12 weeks, respectively). No adverse effects were reported from taking either collagen or placebo.</p></sec><sec id="Sec4"><title>Discussion</title><p id="Par24">The management of knee OA primarily focuses on symptom control and functional improvement. Recently, nutritional supplements, particularly collagen-based products, have garnered interest because of their potential role in cartilage metabolism and promising results in previous studies<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Our study evaluated the efficacy of combined UC-II and hydrolysed collagen supplementation in patients with knee OA. Although both intervention and placebo groups demonstrated significant improvements in pain and functional outcomes over the 12-week study period, no significant differences were observed between the groups across all measured parameters, including pain intensity, functional scores, rescue medication consumption, and patient satisfaction.</p><p id="Par25">These findings differ from those of several previous studies that have examined UC-II supplementation alone. Sadigursky et al.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> reported significant improvements in both Western Ontario and McMaster University Arthritis Index (WOMAC) Pain and visual analogue scale (VAS) scores at 30 and 90 d in the UC-II group compared with those in the placebo group. Similarly, Lugo et al.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> observed superior outcomes in the UC-II group across all WOMAC subscales, including significant reductions in pain and VAS scores on day 180.</p><p id="Par26">However, our results aligned more closely with those of Costa et al.,<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> who also found no significant differences between the UC-II and placebo groups.</p><p id="Par27">Regarding functional outcomes, our findings contradicted those of several previous studies. We observed no significant improvements in KOOS scores between the groups; however, Sadigursky et al.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> demonstrated significant enhancements in WOMAC function scores and SF-12 physical components by day 90. Similarly, Lugo et al.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> reported superior outcomes across all functional parameters in the UC-II group on day 180.</p><p id="Par28">When comparing our results with those of previous studies on hydrolysed collagen, we found similar disparities. While earlier research by Tr&#269; and Bohmov&#225;<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, Benito-Ruiz et al.,<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and Bruy&#232;re et al.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> reported superior pain relief with collagen hydrolysate compared with control interventions, our combined supplementation approach did not yield similar benefits. Notably, Tr&#269; and Bohmov&#225;<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> demonstrated that compared with glucosamine sulphate, enzymatic hydrolysed collagen resulted in significant VAS improvements, while Benito-Ruiz et al.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> observed marked improvements in both VAS and WOMAC scores, particularly among severe OA cases.</p><p id="Par29">The discrepancy between our findings and those of previous studies may be attributed to several factors including supplement formulation variations, dosing regimens, study durations, and patient populations.</p><p id="Par30">Notably, previous trials of individual collagen products such as Lugo et al.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>Sadigursky et al.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>and Benito-Ruiz et al.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> reported significant improvements in pain and function with intervention durations of 90 days to 6 months. In contrast, our study assessed a combined formulation over a shorter 12-week period. It is possible that the clinical benefits of collagen supplementation, particularly those related to cartilage metabolism and repair, may require longer durations to become detectable. The relatively short timeframe in our study may therefore have limited the ability to observe meaningful differences between groups.</p><p id="Par31">The absence of superior outcomes in the combined supplementation group may suggest a lack of synergistic interaction between UC-II and hydrolysed collagen. These two compounds may even compete for absorption or bioactivity pathways. Additionally, the dosages used in this study (20&#160;mg UC-II and 480&#160;mg hydrolysed collagen) may be suboptimal when administered together. The fixed dosing may not reflect the ideal ratio or threshold needed for synergistic effects. Future studies should explore optimal dosing strategies, timing of administration, and potential pharmacokinetic interactions between these agents to determine whether combined use can offer additive or synergistic clinical benefits.</p><p id="Par32">Our study has several limitations. First, the 12-week follow-up period may have been insufficient to detect the long-term effects of collagen supplementation on cartilage metabolism and clinical outcomes, as the biological effects of nutritional interventions often require extended durations to manifest. Second, the relatively small sample size may have resulted in insufficient statistical power to detect small but potentially clinically meaningful effects. A post hoc power analysis using the observed between-group difference in pain reduction (0.08 on the VNRS) and an estimated standard deviation of 2.0 yielded a very small effect size (Cohen&#8217;s d&#8201;=&#8201;0.04), corresponding to only 5.3% power with our current sample size (<italic toggle="yes">n</italic>&#8201;=&#8201;34 per group). Based on conventional estimates for nutraceutical trials, a small-to-moderate effect size (Cohen&#8217;s d&#8201;=&#8201;0.3) would require approximately 235 participants per group to achieve 90% power at a 0.05 significance level. Therefore, the null findings should be interpreted cautiously, as the study may have been underpowered to detect subtle benefits. Future research with larger sample sizes is warranted to more definitively assess efficacy.</p><p id="Par33">Third, the study did not include objective biomarkers, imaging data, or pharmacokinetic assessments, which limits our ability to evaluate potential disease-modifying effects or confirm treatment adherence. Future studies should consider incorporating serum or synovial biomarkers, pharmacokinetic analyses, or imaging modalities such as MRI to better understand the biological impact of collagen supplementation and to verify compliance. Additionally, the single-centre recruitment and predominance of moderate knee OA cases (Kellgren&#8211;Lawrence grade 2&#8211;3) may limit the generalisability of our findings to patients with varying disease severities or from different clinical settings. Although rescue medication consumption was monitored, individual variations in pain threshold and medication usage behaviours could have influenced analgesic patterns. Nonetheless, the randomised double-blind design and comprehensive assessment of both objective and patient-reported outcomes provide robust support for our primary conclusions.</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par34">This randomised double-blind trial demonstrated that combined supplementation with UC-II and hydrolysed collagen over 12 weeks provided no additional benefit compared with that of placebo in patients with knee OA. Although both groups showed improvements, the lack of between-group differences suggested that these changes may reflect the natural disease course or placebo effect. Longer-term multicentre studies are needed to fully evaluate the potential benefits of combined collagen supplementation in specific OA populations.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>VY: Study design, data collection, statistical analysis, and writing the paper; PT, TH : Data collection; CA : Study design, statistical analysis, and writing the paper; KI: Corresponding author, study design, data collection, and writing the paper. All authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The research publication received funding support from the Medical Council of Thailand (Police General Dr. Jongjate Aojanepong Foundation).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during this current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par35">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par36">This study was approved by the Ethics Committee and Institutional Review Board of the Faculty of Medicine, Prince of Songkla University.</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par37">Informed consent was obtained from all individual participants included in the study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Szilagyi, I. A. et al. Metabolic syndrome, radiographic osteoarthritis progression and chronic pain of the knee among men and women from the general population: the Rotterdam study. <italic toggle="yes">Semin. Arthritis Rheum.</italic>10.1016/j.semarthrit.2024.152544.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semarthrit.2024.152544</pub-id><pub-id pub-id-type="pmid">39288696</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>E</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name></person-group><article-title>Global burden and socioeconomic impact of knee osteoarthritis: a comprehensive analysis</article-title><source>Front. Med. (Lausanne)</source><year>2024</year><volume>11</volume><fpage>1323091</fpage><pub-id pub-id-type="doi">10.3389/fmed.2024.1323091</pub-id><pub-id pub-id-type="pmid">38818397</pub-id><pub-id pub-id-type="pmcid">PMC11137242</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Li, E., Tan, J., Xu, K., Pan, Y. &amp; Xu, P. Global burden and socioeconomic impact of knee osteoarthritis: a comprehensive analysis. <italic toggle="yes">Front. Med. (Lausanne)</italic>. <bold>11</bold>, 1323091. 10.3389/fmed.2024.1323091 (2024).<pub-id pub-id-type="pmid">38818397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1323091</pub-id><pub-id pub-id-type="pmcid">PMC11137242</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>R</given-names></name></person-group><article-title>Temporal trends in the disease burden of osteoarthritis from 1990 to 2019, and projections until 2030</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><fpage>e0288561</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0288561</pub-id><pub-id pub-id-type="pmid">37486949</pub-id><pub-id pub-id-type="pmcid">PMC10365297</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chen, X., Tang, H., Lin, J. &amp; Zeng, R. Temporal trends in the disease burden of osteoarthritis from 1990 to 2019, and projections until 2030. <italic toggle="yes">PLoS One</italic>. <bold>18</bold>, e0288561. 10.1371/journal.pone.0288561 (2023).<pub-id pub-id-type="pmid">37486949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0288561</pub-id><pub-id pub-id-type="pmcid">PMC10365297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brophy</surname><given-names>RH</given-names></name><name name-style="western"><surname>Fillingham</surname><given-names>YA</given-names></name></person-group><article-title>AAOS clinical practice guideline summary: management of osteoarthritis of the knee (nonarthroplasty), third edition</article-title><source>J. Am. Acad. Orthop. Surg.</source><year>2022</year><volume>30</volume><fpage>e721</fpage><lpage>e729</lpage><pub-id pub-id-type="doi">10.5435/JAAOS-D-21-01233</pub-id><pub-id pub-id-type="pmid">35383651</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Brophy, R. H. &amp; Fillingham, Y. A. AAOS clinical practice guideline summary: management of osteoarthritis of the knee (nonarthroplasty), third edition. <italic toggle="yes">J. Am. Acad. Orthop. Surg.</italic><bold>30</bold>, e721&#8211;e729. 10.5435/JAAOS-D-21-01233 (2022).<pub-id pub-id-type="pmid">35383651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5435/JAAOS-D-21-01233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>AK</given-names></name><etal/></person-group><article-title>American academy of orthopaedic surgeons clinical practice guideline summary of surgical management of osteoarthritis of the knee</article-title><source>J. Am. Acad. Orthop. Surg.</source><year>2023</year><volume>31</volume><fpage>1211</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.5435/JAAOS-D-23-00338</pub-id><pub-id pub-id-type="pmid">37883429</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Srivastava, A. K. et al. American academy of orthopaedic surgeons clinical practice guideline summary of surgical management of osteoarthritis of the knee. <italic toggle="yes">J. Am. Acad. Orthop. Surg.</italic><bold>31</bold>, 1211&#8211;1220. 10.5435/JAAOS-D-23-00338 (2023).<pub-id pub-id-type="pmid">37883429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5435/JAAOS-D-23-00338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcaide-Ruggiero</surname><given-names>L</given-names></name><name name-style="western"><surname>Molina-Hern&#225;ndez</surname><given-names>V</given-names></name><name name-style="western"><surname>Granados</surname><given-names>MM</given-names></name><name name-style="western"><surname>Dom&#237;nguez</surname><given-names>JM</given-names></name></person-group><article-title>Main and minor types of collagens in the articular cartilage: the role of collagens in repair tissue evaluation in Chondral defects</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><fpage>13329</fpage><pub-id pub-id-type="doi">10.3390/ijms222413329</pub-id><pub-id pub-id-type="pmid">34948124</pub-id><pub-id pub-id-type="pmcid">PMC8706311</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Alcaide-Ruggiero, L., Molina-Hern&#225;ndez, V., Granados, M. M. &amp; Dom&#237;nguez, J. M. Main and minor types of collagens in the articular cartilage: the role of collagens in repair tissue evaluation in Chondral defects. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>22</bold>, 13329. 10.3390/ijms222413329 (2021).<pub-id pub-id-type="pmid">34948124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms222413329</pub-id><pub-id pub-id-type="pmcid">PMC8706311</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Coronado</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials</article-title><source>Int. Orthop.</source><year>2019</year><volume>43</volume><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1007/s00264-018-4211-5</pub-id><pub-id pub-id-type="pmid">30368550</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Garc&#237;a-Coronado, J. M. et al. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. <italic toggle="yes">Int. Orthop.</italic><bold>43</bold>, 531&#8211;538. 10.1007/s00264-018-4211-5 (2019).<pub-id pub-id-type="pmid">30368550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00264-018-4211-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cartilage-related collagens in osteoarthritis and rheumatoid arthritis: from pathogenesis to therapeutics</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><fpage>9841</fpage><pub-id pub-id-type="doi">10.3390/ijms24129841</pub-id><pub-id pub-id-type="pmid">37372989</pub-id><pub-id pub-id-type="pmcid">PMC10298547</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ouyang, Z. et al. Cartilage-related collagens in osteoarthritis and rheumatoid arthritis: from pathogenesis to therapeutics. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>24</bold>, 9841. 10.3390/ijms24129841 (2023).<pub-id pub-id-type="pmid">37372989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24129841</pub-id><pub-id pub-id-type="pmcid">PMC10298547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castrogiovanni</surname><given-names>P</given-names></name><etal/></person-group><article-title>Nutraceutical supplements in the management and prevention of osteoarthritis</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><fpage>2042</fpage><pub-id pub-id-type="doi">10.3390/ijms17122042</pub-id><pub-id pub-id-type="pmid">27929434</pub-id><pub-id pub-id-type="pmcid">PMC5187842</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Castrogiovanni, P. et al. Nutraceutical supplements in the management and prevention of osteoarthritis. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>17</bold>, 2042. 10.3390/ijms17122042 (2016).<pub-id pub-id-type="pmid">27929434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms17122042</pub-id><pub-id pub-id-type="pmcid">PMC5187842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>RD</given-names></name><etal/></person-group><article-title>IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-alpha in human articular chondrocytes in vitro</article-title><source>Cytokine</source><year>2008</year><volume>44</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2008.10.012</pub-id><pub-id pub-id-type="pmid">19026560</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">M&#252;ller, R. D. et al. IL-10 overexpression differentially affects cartilage matrix gene expression in response to TNF-alpha in human articular chondrocytes in vitro. <italic toggle="yes">Cytokine</italic><bold>44</bold>, 377&#8211;385. 10.1016/j.cyto.2008.10.012 (2008).<pub-id pub-id-type="pmid">19026560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2008.10.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Sugihara</surname><given-names>F</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>N</given-names></name><name name-style="western"><surname>Venkateswarathirukumara</surname><given-names>S</given-names></name></person-group><article-title>A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis</article-title><source>J. Sci. Food Agric.</source><year>2015</year><volume>95</volume><fpage>702</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1002/jsfa.6752</pub-id><pub-id pub-id-type="pmid">24852756</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kumar, S., Sugihara, F., Suzuki, K., Inoue, N. &amp; Venkateswarathirukumara, S. A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis. <italic toggle="yes">J. Sci. Food Agric.</italic><bold>95</bold>, 702&#8211;707. 10.1002/jsfa.6752 (2015).<pub-id pub-id-type="pmid">24852756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jsfa.6752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lugo</surname><given-names>JP</given-names></name><name name-style="western"><surname>Saiyed</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Lane</surname><given-names>NE</given-names></name></person-group><article-title>Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study</article-title><source>Nutr. J.</source><year>2016</year><volume>15</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s12937-016-0130-8</pub-id><pub-id pub-id-type="pmid">26822714</pub-id><pub-id pub-id-type="pmcid">PMC4731911</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lugo, J. P., Saiyed, Z. M. &amp; Lane, N. E. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. <italic toggle="yes">Nutr. J.</italic><bold>15</bold>, 14. 10.1186/s12937-016-0130-8 (2016).<pub-id pub-id-type="pmid">26822714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12937-016-0130-8</pub-id><pub-id pub-id-type="pmcid">PMC4731911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiojima</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and safety of dietary undenatured type II collagen on joint and motor function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study</article-title><source>J. Am. Nutr. Assoc.</source><year>2023</year><volume>42</volume><fpage>224</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1080/07315724.2021.2024466</pub-id><pub-id pub-id-type="pmid">35512781</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Shiojima, Y. et al. Efficacy and safety of dietary undenatured type II collagen on joint and motor function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. <italic toggle="yes">J. Am. Nutr. Assoc.</italic><bold>42</bold>, 224&#8211;241. 10.1080/07315724.2021.2024466 (2023).<pub-id pub-id-type="pmid">35512781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07315724.2021.2024466</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benito-Ruiz</surname><given-names>P</given-names></name><etal/></person-group><article-title>A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort</article-title><source>Int. J. Food Sci. Nutr.</source><year>2009</year><volume>60</volume><issue>Suppl 2</issue><fpage>99</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1080/09637480802498820</pub-id><pub-id pub-id-type="pmid">19212858</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Benito-Ruiz, P. et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. <italic toggle="yes">Int. J. Food Sci. Nutr.</italic><bold>60</bold> (Suppl 2), 99&#8211;113. 10.1080/09637480802498820 (2009).<pub-id pub-id-type="pmid">19212858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09637480802498820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schauss</surname><given-names>AG</given-names></name><name name-style="western"><surname>Stenehjem</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Endres</surname><given-names>JR</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>A</given-names></name></person-group><article-title>Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, biocell collagen, on improving osteoarthritis-related symptoms: a randomized, double-blind, placebo-controlled trial</article-title><source>J. Agric. Food Chem.</source><year>2012</year><volume>60</volume><fpage>4096</fpage><lpage>4101</lpage><pub-id pub-id-type="doi">10.1021/jf205295u</pub-id><pub-id pub-id-type="pmid">22486722</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Schauss, A. G., Stenehjem, J., Park, J., Endres, J. R. &amp; Clewell, A. Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, biocell collagen, on improving osteoarthritis-related symptoms: a randomized, double-blind, placebo-controlled trial. <italic toggle="yes">J. Agric. Food Chem.</italic><bold>60</bold>, 4096&#8211;4101. 10.1021/jf205295u (2012).<pub-id pub-id-type="pmid">22486722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jf205295u</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Machado</surname><given-names>GC</given-names></name><name name-style="western"><surname>Eyles</surname><given-names>JP</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>V</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis</article-title><source>Br. J. Sports Med.</source><year>2018</year><volume>52</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1136/bjsports-2016-097333</pub-id><pub-id pub-id-type="pmid">29018060</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Liu, X., Machado, G. C., Eyles, J. P., Ravi, V. &amp; Hunter, D. J. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. <italic toggle="yes">Br. J. Sports Med.</italic><bold>52</bold>, 167&#8211;175. 10.1136/bjsports-2016-097333 (2018).<pub-id pub-id-type="pmid">29018060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjsports-2016-097333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadigursky</surname><given-names>D</given-names></name><etal/></person-group><article-title>Undenatured collagen type II for the treatment of osteoarthritis of the knee</article-title><source>Acta Ortop. Bras.</source><year>2022</year><volume>30</volume><fpage>e240572</fpage><pub-id pub-id-type="doi">10.1590/1413-785220223002240572</pub-id><pub-id pub-id-type="pmid">35765574</pub-id><pub-id pub-id-type="pmcid">PMC9210509</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Sadigursky, D. et al. Undenatured collagen type II for the treatment of osteoarthritis of the knee. <italic toggle="yes">Acta Ortop. Bras.</italic><bold>30</bold>, e240572. 10.1590/1413-785220223002240572 (2022).<pub-id pub-id-type="pmid">35765574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1413-785220223002240572</pub-id><pub-id pub-id-type="pmcid">PMC9210509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Associated strengthening exercises to undenatured oral type II collagen (UC-II). A randomized study in patients affected by knee osteoarthritis</article-title><source>Muscle Ligaments Tendons J.</source><year>2020</year><volume>10</volume><fpage>481</fpage><pub-id pub-id-type="doi">10.32098/mltj.03.2020.18</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Costa, A. P. et al. Associated strengthening exercises to undenatured oral type II collagen (UC-II). A randomized study in patients affected by knee osteoarthritis. <italic toggle="yes">Muscle Ligaments Tendons J.</italic><bold>10</bold>, 481. 10.32098/mltj.03.2020.18 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tr&#269;</surname><given-names>T</given-names></name><name name-style="western"><surname>Bohmov&#225;</surname><given-names>J</given-names></name></person-group><article-title>Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)</article-title><source>Int. Orthop.</source><year>2011</year><volume>35</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1007/s00264-010-1010-z</pub-id><pub-id pub-id-type="pmid">20401752</pub-id><pub-id pub-id-type="pmcid">PMC3047656</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Tr&#269;, T. &amp; Bohmov&#225;, J. Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA). <italic toggle="yes">Int. Orthop.</italic><bold>35</bold>, 341&#8211;348. 10.1007/s00264-010-1010-z (2011).<pub-id pub-id-type="pmid">20401752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00264-010-1010-z</pub-id><pub-id pub-id-type="pmcid">PMC3047656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruy&#232;re</surname><given-names>O</given-names></name><etal/></person-group><article-title>Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study</article-title><source>Complement. Ther. Med.</source><year>2012</year><volume>20</volume><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.ctim.2011.12.007</pub-id><pub-id pub-id-type="pmid">22500661</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Bruy&#232;re, O. et al. Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study. <italic toggle="yes">Complement. Ther. Med.</italic><bold>20</bold>, 124&#8211;130. 10.1016/j.ctim.2011.12.007 (2012).<pub-id pub-id-type="pmid">22500661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctim.2011.12.007</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>